These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers. Fleuranceau-Morel P Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550 [TBL] [Abstract][Full Text] [Related]
4. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. Roberto G; Piccinni C; D'Alessandro R; Poluzzi E Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799 [TBL] [Abstract][Full Text] [Related]
5. Pregnancy exposure registries: academic opportunities and industry responsibility. Wyszynski DF Birth Defects Res A Clin Mol Teratol; 2009 Jan; 85(1):93-101. PubMed ID: 19107953 [TBL] [Abstract][Full Text] [Related]
6. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment. Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863 [TBL] [Abstract][Full Text] [Related]
7. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006. Chang S; Ball R; Braun MM Vaccine; 2008 May; 26(19):2428-32. PubMed ID: 18406499 [TBL] [Abstract][Full Text] [Related]
8. Antiepileptic drugs (AEDs) during pregnancy and risk of congenital jaw and oral malformation. Koo J; Zavras A Oral Dis; 2013 Oct; 19(7):712-20. PubMed ID: 23305414 [TBL] [Abstract][Full Text] [Related]
9. Vitamin K antagonists in pregnancy: an overestimated risk? Peters PW Thromb Haemost; 2006 Jun; 95(6):922-3. PubMed ID: 16732368 [No Abstract] [Full Text] [Related]
10. Reproductive toxicity evaluation of a new camptothecin anticancer agent, CKD-602, in pregnant/lactating female rats and their offspring. Chung MK; Kim CY; Kim JC Cancer Chemother Pharmacol; 2007 Feb; 59(3):383-95. PubMed ID: 16896929 [TBL] [Abstract][Full Text] [Related]
11. Post-marketing surveillance system for drugs in pregnancy--15 years experience of ENTIS. Schaefer C; Hannemann D; Meister R Reprod Toxicol; 2005; 20(3):331-43. PubMed ID: 15978773 [TBL] [Abstract][Full Text] [Related]
12. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. Psaty BM; Furberg CD; Ray WA; Weiss NS JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720 [TBL] [Abstract][Full Text] [Related]
13. Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Colvin L; Slack-Smith L; Stanley FJ; Bower C Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1137-50. PubMed ID: 20602344 [TBL] [Abstract][Full Text] [Related]
14. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Perrio MJ; Wilton LV; Shakir SA Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762 [TBL] [Abstract][Full Text] [Related]
15. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System. Clark JA; Humphries JE; Crean S; Reynolds MW Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051 [TBL] [Abstract][Full Text] [Related]
16. Safety of tetanus toxoid in pregnant women: a hospital-based case-control study of congenital anomalies. Silveira CM; Cáceres VM; Dutra MG; Lopes-Camelo J; Castilla EE Bull World Health Organ; 1995; 73(5):605-8. PubMed ID: 8846486 [TBL] [Abstract][Full Text] [Related]
17. [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005]. Weisser K; Meyer C; Petzold D; Mentzer D; Keller-Stanislawski B Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Nov; 50(11):1404-17. PubMed ID: 17999134 [TBL] [Abstract][Full Text] [Related]
18. Monitoring for teratogenic signals: pregnancy registries and surveillance methods. Howard TB; Tassinari MS; Feibus KB; Mathis LL Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):209-14. PubMed ID: 21766431 [TBL] [Abstract][Full Text] [Related]
19. Identifying, evaluating and quantifying adverse drug reactions in children: opportunities and obstacles for the manufacturer. Bruppacher R; Gelzer J Bratisl Lek Listy; 1991 Nov; 92(11):549-53. PubMed ID: 1806167 [TBL] [Abstract][Full Text] [Related]
20. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Wysowski DK; Swartz L Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]